Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352883 · ClinicalTrials.gov registry record · NA
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
A NA study of Ductal Breast Carcinoma in Situ, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- NA
- Development phase
- 368
- Enrollment target
- 20
- Study locations
NCT02352883 is a NA study of Ductal Breast Carcinoma in Situ that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 368 participants, above the 118-participant average among 11 other Ductal Breast Carcinoma in Situ trials with a reported enrollment target (212% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT02352883, a NA study of Ductal Breast Carcinoma in Situ, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 368 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. MRI may help find and diagnose patients with breast cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. Genetic studies may help doctors predict the outcome of treatment and the risk for disease recurrence. Performing MRI with genetic studies may help determine the best treatment for patients with breast cancer in situ.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- RADIATION Radiation Therapy
- PROCEDURE Therapeutic Conventional Surgery
- PROCEDURE Therapeutic Surgical Procedure
- DRUG Endocrine Therapy
Study Locations (20)
Illinois
- Northwestern University - Chicago
- Ingalls Memorial Hospital - Harvey
- Edward Hospital/Cancer Center - Naperville
- Edward Hospital/Cancer Center?Plainfield - Plainfield
- Springfield Clinic - Springfield
- Memorial Medical Center - Springfield
Connecticut
- Greenwich Hospital - Greenwich
- Hartford Hospital - Hartford
- Midstate Medical Center - Meriden
- The Hospital of Central Connecticut - New Britain
Delaware
- Helen F Graham Cancer Center - Newark
- Medical Oncology Hematology Consultants PA - Newark
- Regional Hematology and Oncology PA - Newark
- Christiana Care Health System-Christiana Hospital - Newark
Indiana
- IU Health West Hospital - Avon
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
- Memorial Regional Cancer Center Day Road - Mishawaka
California
- Kaiser Permanente-San Diego Zion - San Diego
- Kaiser Permanente-San Marcos - San Marcos
Florida
- John Fitzgerald Kennedy Medical Center - Atlantis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2015-03-25 |
| Est. Completion | 2027-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02352883
The ClinicalTrials.gov registry entry for NCT02352883 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 368 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 118-participant average among 11 other Ductal Breast Carcinoma in Situ trials with a reported enrollment target (212% higher). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ductal Breast Carcinoma in Situ appearing as the primary indexed condition, and to 5 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT02352883 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Connecticut, Delaware.
Frequently Asked Questions
What is clinical trial NCT02352883 about?
NCT02352883 is a clinical study titled "MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ". This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. ...
What is the current status of trial NCT02352883?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 368 participants. The study started on 2015-03-25. Estimated completion is 2027-11.
What conditions does trial NCT02352883 study?
This clinical trial studies the following conditions: Ductal Breast Carcinoma in Situ.
What interventions are being tested in trial NCT02352883?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Radiation Therapy (RADIATION), Therapeutic Conventional Surgery (PROCEDURE), Therapeutic Surgical Procedure (PROCEDURE), Endocrine Therapy (DRUG).
Who is sponsoring clinical trial NCT02352883?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02352883 being conducted?
This trial has 20 study locations across California, Connecticut, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ductal Breast Carcinoma in Situ
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
RECRUITING · NA
-
Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants
ACTIVE NOT RECRUITING · NA
-
Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM)
ACTIVE NOT RECRUITING · NA
-
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
RECRUITING · Phase 2
-
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.